Sihuan Pharmaceutical Holdings Group (0460) Price & Analysis

Compare

1 Followers

0460 Stock Chart & Stats

HK$1.32

HK$0.00(0.00%)

At close: Jan 09 4:00 PM EST

HK$1.32

HK$0.00(0.00%)

Day’s Range― - ―

52-Week RangeHK$0.53 - HK$1.92

Previous CloseN/A

Volume8.01M

Average Volume (3M)37.54M

Market Cap

HK$15.30B

Enterprise ValueHK$11.08B

Total Cash (Recent Filing)HK$3.60B

Total Debt (Recent Filing)HK$1.03B

Price to Earnings (P/E)―

Beta1.04

Next Earnings

Mar 31, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.87%

Share Statistics

EPS (TTM)0.01

Shares Outstanding9,329,999,000

10 Day Avg. Volume24,963,024

30 Day Avg. Volume37,542,935

Financial Highlights & Ratios

PEG Ratio-0.09

Price to Book (P/B)1.31

Price to Sales (P/S)3.02

P/FCF Ratio99.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Therapeutic Diversification & Proprietary DrugsBroad exposure across cardiovascular, CNS and anti-infection markets plus proprietary products reduces single-product risk and supports multiple revenue streams. This durable portfolio mix helps steady revenue when individual drug lifecycles fluctuate and aids long-term commercialization potential.

Established Distribution And PartnershipsDeep relationships with hospitals, clinics and distributors create durable go-to-market channels for both RX and OTC products in China. These partnerships lower commercialization friction for new launches, sustain product turnover, and provide structural support for scaling sales across geographies and care settings.

Low Financial LeverageA low debt profile reduces refinancing and interest-rate risk, preserving strategic flexibility. That balance-sheet room supports continued R&D investment or working-capital management during cyclical revenue weakness, enabling the company to pursue recovery without immediate solvency pressure.

Bears Say

Multi-year Revenue DeclineA sustained fall in top-line over several years signals weakening market share, potential product obsolescence, or commercialization gaps. That trend undermines scale economics, strains R&D payback, and makes profitable growth harder absent successful new launches or market re-expansion initiatives.

Persistent Losses And Negative MarginsOngoing net losses and negative operating margins indicate structural profitability issues—whether pricing, cost base, or product mix. Without sustained margin recovery, the company will struggle to self-fund innovation and operations, increasing reliance on external capital and constraining strategic options.

Volatile And Negative Cash FlowErratic operating cash generation and recent negative free cash flow create persistent liquidity risk and limit ability to invest in R&D or commercial expansion. Structural cash volatility raises the probability of management needing external financing, diluting shareholders or forcing cost cuts that impair long-term growth.

Sihuan Pharmaceutical Holdings Group News

Sihuan Subsidiary Xuanzhu Biopharm Joins Hang Seng Composite Index, Opening Path to Stock Connect

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has shared an update. Xuanzhu Biopharmaceutical, the innovative drug arm of...

10h ago

Sihuan Pharmaceutical Forecasts Strong 2025 Profit on Booming Aesthetics and Drug Growth

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has provided an announcement. Sihuan Pharmaceutical issued a positive profit alert,...

12d ago

Sihuan Pharmaceutical Expands PLLA Filler Range With Six New NMPA-Approved Specifications

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical announced that its subsidiary Meiyan...

1M ago

Sihuan Pharmaceutical Launches Share Buyback Amid Pivotal Turnaround and Aesthetics-Led Growth

An announcement from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical has launched a...

2M ago

Sihuan Pharma Buys 9 Million Shares for Award Scheme as Dual-Drive Strategy Advances

The latest update is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical Holdings Group has...

2M ago

Sihuan Pharmaceutical’s Anjiuwei Secures Spot in 2025 NRDL, Boosting Market Prospects

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical Holdings Group announced...

3M ago

Sihuan Pharmaceutical’s Innovative Drug Xuanyuening Gains NRDL Inclusion

An update from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) is now available. Sihuan Pharmaceutical Holdings Group Ltd....

3M ago

Sihuan Pharmaceutical’s Xuanzhu Biopharma Plans H Share Full Circulation

The latest announcement is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical Holdings Group Ltd....

3M ago

Sihuan Pharmaceutical Partners with Abalone Bio for Innovative Obesity Therapy

Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ) has issued an update. Sihuan Pharmaceutical Holdings Group Ltd. has signed...

4M ago

Sihuan Pharmaceutical’s NG-350A Receives FDA Fast Track Designation

The latest update is out from Sihuan Pharmaceutical Holdings Group ( ($HK:0460) ). Sihuan Pharmaceutical Holdings Group Ltd....

4M ago

0460 FAQ

What was Sihuan Pharmaceutical Holdings Group Ltd.’s price range in the past 12 months?

Sihuan Pharmaceutical Holdings Group Ltd. lowest stock price was HK$0.53 and its highest was HK$1.92 in the past 12 months.

What is Sihuan Pharmaceutical Holdings Group Ltd.’s market cap?

Sihuan Pharmaceutical Holdings Group Ltd.’s market cap is HK$15.30B.

When is Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date?

Sihuan Pharmaceutical Holdings Group Ltd.’s upcoming earnings report date is Mar 31, 2026 which is in 37 days.

How were Sihuan Pharmaceutical Holdings Group Ltd.’s earnings last quarter?

Sihuan Pharmaceutical Holdings Group Ltd. released its earnings results on Aug 29, 2025. The company reported HK$0.012 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.012.

Is Sihuan Pharmaceutical Holdings Group Ltd. overvalued?

According to Wall Street analysts Sihuan Pharmaceutical Holdings Group Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sihuan Pharmaceutical Holdings Group Ltd. pay dividends?

Sihuan Pharmaceutical Holdings Group Ltd. pays a Annually dividend of HK$0.011 which represents an annual dividend yield of 0.87%. See more information on Sihuan Pharmaceutical Holdings Group Ltd. dividends here

What is Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate?

Sihuan Pharmaceutical Holdings Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sihuan Pharmaceutical Holdings Group Ltd. have?

Sihuan Pharmaceutical Holdings Group Ltd. has 9,329,999,000 shares outstanding.

What happened to Sihuan Pharmaceutical Holdings Group Ltd.’s price movement after its last earnings report?

Sihuan Pharmaceutical Holdings Group Ltd. reported an EPS of HK$0.012 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.329%.

Which hedge fund is a major shareholder of Sihuan Pharmaceutical Holdings Group Ltd.?

Currently, no hedge funds are holding shares in HK:0460

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Sihuan Pharmaceutical Holdings Group Stock Smart Score

Outperform

Technicals

Fundamentals

Return on Equity

-1.87%

Trailing 12-Months

Asset Growth

-6.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sihuan Pharmaceutical Holdings Group Ltd.

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in the People's Republic of China. It offers drugs in the oncology, metabolic diseases, digestive system, and other therapeutic areas. The company is also involved in the investment and sale of medical beauty products; manufacture of medical instruments; investment in properties; construction for medical projects; and project preparation for pharmaceutical products manufacturing. In addition, it provides information support, general hospital, hospital management, biotechnology promotion, and medical aesthetic research and development services. The company was founded in 2001 and is based in Wanchai, Hong Kong.